Maze Therapeutics Inc. (MAZE)
Maze Therapeutics Inc. (MAZE) Stock Price, Analysis & Data
| Bid | 19.91 |
| Market Cap | 1.52B |
| Revenue (ttm) | 20M |
| Net Income (ttm) | -122.54M |
| Beta | n/a |
| EPS (ttm) | -2.35 |
| PE Ratio (ttm) | n/a |
| Forward PE | -8.85 |
| P/B (ttm) | 3.97 |
| P/S (ttm) | 76.18 |
| Earnings Date | Nov 5, 2026 |
| Ask | 35.55 |
| Volume | 439,096 |
| Avg. Volume (20D) | 573,174 |
| Open | 27.48 |
| Previous Close | 27.31 |
| Day's Range | 26.82 - 27.86 |
| 52-Week Range | 12.81 - 53.65 |
| Analyst | Strong Buy |
| Price Target | 55 (99.78%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready c...
Financial Performance
In 2025, Maze Therapeutics's revenue was 0, a decrease of -100% compared to the previous year's 167.5M. Earnings were -131.12M, a decrease of -351.04%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for MAZE stock is "Strong Buy". The 12-month stock price forecast is 55, which is upside of 99.78% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
